Roche
6 stories in The Vital Record · Company
-
· FDA & Regulatory
FDA Accepts Giredestrant NDA Under Priority Review for Early ER+ Breast Cancer — Decision Due November 30 -
· Clinical Trials
Roche Terminates Phase 3 SKYSCRAPER-15 Tiragolumab Trial in Resected NSCLC, Deepening TIGIT Setbacks -
· Biotech Business
Roche pays Nurix $700M upfront for investigational BTK degrader, in pact worth up to $2.3B -
· Research
An investigational lymphoma antibody cleared more protein than tacrolimus in a hard-to-treat kidney-disease trial -
· Opinion
When the challenger loses to the standard of care, listen -
· Clinical Trials
Roche's investigational TIGIT antibody tiragolumab loses head-to-head to pembrolizumab in a lung-cancer trial